Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2020, with the report issued on July 24, 2020. The filing announces a significant regulatory milestone for GSK's oncology portfolio regarding the investigational drug belantamab mafodotin.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a current report focused on a regulatory development rather than a financial statement.
Material Changes and Regulatory Developments
The primary material event is the adoption of a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The CHMP recommends the approval of belantamab mafodotin as a monotherapy for adult patients with relapsed and refractory multiple myeloma who have received at least four prior therapies and are refractory to specific drug classes.
- Regulatory Status: The positive opinion is a final step before marketing authorisation by the European Commission. If approved, the drug will be marketed as BLENREP.
- US Status: The drug is under priority review by the US Food and Drug Administration (FDA) for its Biologics License Application (BLA).
- Designation: The drug received PRIME designation in 2017 and was reviewed under the EMA's accelerated assessment procedure.
Clinical Data, Outlook, and Risks
Management commentary highlights that this approval would provide a first-in-class anti-BCMA treatment option for patients with limited choices. The recommendation is based on data from the pivotal DREAMM-2 study with 13-month follow-up.
Clinical Trial Results (DREAMM-2)
- Overall Response Rate: 32% for the 2.5 mg/kg dose administered every three weeks.
- Median Duration of Response: 11 months.
- Median Overall Survival: 13.7 months.
Safety Profile
The safety profile was consistent with previously reported data. Common grade 3 or higher adverse events (occurring in >10% of patients on the 2.5 mg/kg dose) included:
- Keratopathy/microcyst-like epithelial changes (MECs): 46%
- Thrombocytopenia: 22%
- Anaemia: 21%
- Lymphocyte count decreased: 13%
- Neutropenia: 11%
Risks and Contingencies
GSK includes a cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in the 2019 Form 20-F and impacts from the COVID-19 pandemic. The drug is not currently approved for use anywhere in the world pending final regulatory decisions.
Investor Verification Checklist
- Confirm the final marketing authorisation decision by the European Commission following the CHMP positive opinion.
- Monitor the FDA's decision on the Biologics License Application (BLA) for belantamab mafodotin.
- Review the commercial launch strategy and pricing for BLENREP in the European Union.
- Assess the long-term safety data regarding keratopathy and other adverse events as post-marketing surveillance begins.
- Track the progress of ongoing Phase III trials (DREAMM-3, DREAMM-7, DREAMM-9) to evaluate the drug's efficacy in combination therapies and earlier lines of treatment.